About the Company
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. Intellia's proprietary non-viral gene knock out platform deploys lipid nanoparticles to deliver to the liver a two-part genome editing system: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 enzyme, which carries out the precision editing. Intellia also has a number of research programs for in vivo and ex vivo therapeutic candidates with potential applications in diseases including cancer, alpha-1 antitrypsin deficiency, and hemophilia. The company is also working on a variety of additional gene editing technologies including base editing and DNA writing.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Intellia Therapeutics, Inc.
Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest second-quarter results and things are looking bullish. Revenues were better than expected, with US$14m in revenue some 17% ahead of ...
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Intellia Therapeutics, Inc.'s gene-editing therapies show strong potential with robust efficacy, safety, and market demand.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) ...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of ...
Intellia Therapeutics Stock Performance NASDAQ:NTLA opened at $14.24 on Thursday. The firm has a market capitalization of $1.47 billion, a PE ratio of -2.72 and a beta of 2.21. The stock has a 50 ...
Intellia Therapeutics’ Earnings Call Highlights Progress and Challenges
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
Intellia Therapeutics to Present Q4 and Full-Year 2024 ... - Nasdaq
Intellia Therapeutics, Inc. will hold a conference call on February 27, 2025, at 8 a.m. ET to present its fourth quarter and full-year 2024 financial results and operational highlights.
Intellia Therapeutics, Inc. Sued for Securities Law Violations ...
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal ...
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings ... - Nasdaq
Before you invest in Intellia Therapeutics, Inc. (NTLA), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead ...
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. (NASDAQ: NTLA) securities between June 30 ...
Intellia Therapeutics, Inc. Sued for Securities Law Violations ...
News GlobeNewswire Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NTLA ...
Similar Companies
Loading the latest forecasts...